GBIO Generation Bio

Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference

Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th at 12:45 p.m. ET.

A live webcast of the presentation will be available on the investor section of the company’s website at . A replay will be available there for 30 days following the event.  

About Generation Bio

Generation Bio is a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases. The company is developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. Generation Bio’s innovative approach leverages cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) to T cells. This combination of selective delivery and an intracellular, genetically precise mechanism of target engagement could unlock a series of high-value, historically undruggable disease-driving genes in autoimmunity.

For more information, please visit .

Investors and Media Contact

Maren Killackey

Generation Bio



857-371-4638



EN
02/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Generation Bio

 PRESS RELEASE

Generation Bio to Present at the Needham 24th Annual Virtual Healthcar...

Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th at 12:45 p.m. ET. A live webcast of the presentation will be available on the investor section of the company’s website at . A repla...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

Generation Bio Reports Business Highlights and Fourth Quarter and Full...

Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results -  Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases -  Lead target and indication to be announced MY 2025 -  Cash balance of $185.2 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., March 13, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune dis...

 PRESS RELEASE

Generation Bio to Present at the TD Cowen 45th Annual Health Care Conf...

Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 a.m. ET in Boston. A live webcast of the presentation will be available on the investor section of the company’s website at . A replay will be available there ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch